November 23, 2016 - By Peter Erickson · 0 Comments
The stock of Affimed NV (NASDAQ:AFMD) registered an increase of 0.76% in short interest. AFMD’s total short interest was 755,400 shares in November as published by FINRA. Its up 0.76% from 749,700 shares, reported previously. With 78,000 shares average volume, it will take short sellers 10 days to cover their AFMD’s short positions. The short interest to Affimed NV’s float is 6.56%. The stock last traded at $2.35 per share. It is down 44.71% since April 21, 2016 and is downtrending. It has underperformed by 50.04% the S&P500.
Affimed N.V. is a clinical-stage biopharmaceutical firm focused on discovering and developing cancer immunotherapies. The company has a market cap of $74.95 million. The Company’s product candidates are developed in the field of immuno-oncology, which represents an approach to cancer research that seeks to harness the body’s own immune system to fight tumor cells. It currently has negative earnings. The Company’s pipeline includes FM13, AFM11, AFM21, AFM22, AFM24, TandAb and Trispecific Abs.
Out of 7 analysts covering Affimed Therapeutics (NASDAQ:AFMD), 4 rate it a “Buy”, 0 “Sell”, while 3 “Hold”. This means 57% are positive. Affimed Therapeutics has been the topic of 13 analyst reports since August 6, 2015 according to StockzIntelligence Inc. The stock of Affimed NV (NASDAQ:AFMD) earned “Market Perform” rating by Leerink Swann on Friday, August 12. The stock of Affimed NV (NASDAQ:AFMD) earned “Hold” rating by Zacks on Thursday, September 3. The stock has “Outperform” rating given by Wells Fargo on Friday, December 4. BMO Capital Markets initiated Affimed NV (NASDAQ:AFMD) on Tuesday, April 12 with “Outperform” rating. The firm has “Buy” rating given on Thursday, December 10 by Laidlaw. The firm has “Hold” rating by Jefferies given on Wednesday, September 9. The company was downgraded on Thursday, May 19 by Leerink Swann. On Thursday, August 6 the stock rating was maintained by Oppenheimer with “Outperform”. On Monday, August 10 the stock rating was upgraded by Zacks to “Sell”. Jefferies maintained it with “Hold” rating and $4 target price in Thursday, May 19 report.
Affimed N.V., incorporated on May 1, 2014, is a clinical-stage biopharmaceutical firm focused on discovering and developing cancer immunotherapies. The Company’s product candidates are developed in the field of immuno-oncology, which represents an approach to cancer research that seeks to harness the body’s own immune system to fight tumor cells. The Company’s research and development pipeline consists of AFM13, AFM11, AFM21, AFM22, AFM24, TandAb and Trispecific Abs. The Firm generates its pipeline of product candidates from three platform technologies based on its tetravalent antibody architecture characterized by four binding domains, creating bispecific NK-cell and T-cell TandAbs (binding to two different targets) and Trispecific Abs (binding to three different targets). The Company’s bispecific antibodies, TandAbs, are designed to direct and establish a bridge between either Natural Killer (NK)-cells or T-cells and cancer cells. The Company’s TandAbs brings NK-cells or T-cells into proximity and triggers a signal cascade that leads to the destruction of cancer cells.
More news for Affimed NV (NASDAQ:AFMD) were recently published by: Quotes.Wsj.com, which released: “Affimed NV AFMD (US: Nasdaq)” on September 05, 2014. Zacks.com‘s article titled: “Should You Get Rid of Affimed N.V. (AFMD) Now?” and published on August 14, 2015 is yet another important article.
Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.
By Peter Erickson